优化非肌层浸润性膀胱癌BCG失败分类
该多中心国际队列纳入3806例BCG治疗患者,其中591例BCG后出现高级别NMIBC复发。按IBCG定义,BCG无应答与BCG暴露者预后相似;细化五亚组后预后异质,充分BCG后晚期复发与无应答相当,极晚期复发预后较好。
要点
- BCG无应答与BCG暴露者PFS、CSM、OM无显著差异。
- 充分BCG后6-24个月复发者5年进展率32.5%,与无应答29%相当。
- 极晚期复发(>24个月)5年进展率仅14%,预后较好。
核心结论
- 按IBCG定义,BCG无应答与BCG暴露NMIBC预后相似均较差。
- 细化分类显示预后异质,充分BCG后晚期复发与无应答相当,极晚期复发预后较好。
研究设计与样本
- 多中心国际队列研究,3806例BCG治疗患者中纳入591例BCG后高级别NMIBC复发者(2003-2024年)。
- 主要终点为无进展生存期(PFS),次要终点为癌症特异性死亡(CSM)和总死亡(OM)。
主要发现
- BCG无应答与BCG暴露者PFS、CSM、OM相似(均P>0.05)。
- 5年进展率:BCG无应答29%,充分BCG后6-24个月晚期复发32.5%,BCG暴露且BCG不足(诱导后<24个月)30%,BCG抵抗6.2%,极晚期复发(末次BCG后>24个月)14%(P<0.01)。
- 多因素分析示BCG暴露且BCG不足(sHR 3.42,95%CI 1.33-8.84)、晚期复发(sHR 3.74,95%CI 1.59-8.78)、BCG无应答(sHR 2.34,95%CI 1.00-5.44)较极晚期复发进展风险更高。
关键数值与推荐
- BCG无应答与BCG暴露定义采用IBCG标准。
- 亚组划分:BCG无应答、充分BCG后6-24个月晚期复发、BCG暴露且BCG不足(诱导后<24个月)、BCG抵抗、极晚期复发(末次BCG后>24个月)。
临床怎么用
- 临床可依据细化亚组评估进展风险,充分BCG后晚期复发者应按BCG无应答管理。
- 极晚期复发者进展风险较低,可考虑更保守的随访或治疗策略。
局限性
- 回顾性设计。
- 治疗异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate International Bladder Cancer Group (IBCG) definitions of Bacillus Calmette-Guérin (BCG)-unresponsive and BCG-exposed non-muscle-invasive bladder cancer (NMIBC) and assess prognostic heterogeneity across various BCG-failure types. PATIENTS AND METHODS: From a multicentre international cohort of 3806 BCG-treated patients, 591 who developed high-grade NMIBC recurrence following BCG between 2003 and 2024 were included. Progression-free survival (PFS) was the primary endpoint; cancer-specific (CSM) and overall mortality (OM) were secondary endpoints. Cumulative incidence functions, competing-risk models and multivariable Cox regression were used. RESULTS: Patients with BCG-unresponsive and BCG-exposed disease showed similar PFS, CSM, and OM (all P > 0.05). When stratified into five subgroups, prognosis varied: 5-year progression rates were 29% for BCG-unresponsive, 32.5% for late relapse (between 6 and 24 months) after adequate BCG, 30% for BCG-exposed with inadequate BCG (<24 months from induction), 6.2% for BCG-resistant, and 14% for very late relapse (>24 months since last BCG) (P < 0.01). In multivariable analysis, BCG-exposed after inadequate BCG (subdistribution hazard ratio [sHR] 3.42, 95% confidence interval [CI] 1.33-8.84), late relapse (sHR 3.74, 95% CI 1.59-8.78), and BCG-unresponsive (sHR 2.34, 95% CI 1.00-5.44) were associated with higher progression risks compared to very late relapse. Limitations include retrospective design and treatment heterogeneity. CONCLUSIONS: Under IBCG definitions, BCG-unresponsive and BCG-exposed NMIBC have similarly poor outcomes. A refined classification reveals prognostic heterogeneity, with late relapses after adequate BCG demonstrating outcomes comparable to BCG-unresponsive, and very late relapses conferring better prognosis.
引用
- Ślusarczyk A, Scilipoti P, Contieri R, et al. Refining BCG-failure classifications in non-muscle-invasive bladder cancer. BJU Int. 2026. PMID: 41858138. doi:10.1111/bju.70231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。